CN103298483B - 具有增加的比活性的抗血友病因子viii的新型变体 - Google Patents

具有增加的比活性的抗血友病因子viii的新型变体 Download PDF

Info

Publication number
CN103298483B
CN103298483B CN201180063748.0A CN201180063748A CN103298483B CN 103298483 B CN103298483 B CN 103298483B CN 201180063748 A CN201180063748 A CN 201180063748A CN 103298483 B CN103298483 B CN 103298483B
Authority
CN
China
Prior art keywords
fviii
factor viii
variant
amino acids
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180063748.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN103298483A (zh
Inventor
黎志刚
R·K·斯塔福德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Hundred Deep Co
Hundred Deep LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hundred Deep Co, Hundred Deep LLC filed Critical Hundred Deep Co
Publication of CN103298483A publication Critical patent/CN103298483A/zh
Application granted granted Critical
Publication of CN103298483B publication Critical patent/CN103298483B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201180063748.0A 2010-11-05 2011-11-04 具有增加的比活性的抗血友病因子viii的新型变体 Active CN103298483B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41043710P 2010-11-05 2010-11-05
US61/410,437 2010-11-05
PCT/US2011/059297 WO2012061689A2 (en) 2010-11-05 2011-11-04 A new variant of antihemophilic factor viii having increased specific activity

Publications (2)

Publication Number Publication Date
CN103298483A CN103298483A (zh) 2013-09-11
CN103298483B true CN103298483B (zh) 2017-04-12

Family

ID=46025129

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180063748.0A Active CN103298483B (zh) 2010-11-05 2011-11-04 具有增加的比活性的抗血友病因子viii的新型变体

Country Status (18)

Country Link
US (2) US9150637B2 (https=)
EP (1) EP2635297B1 (https=)
JP (1) JP5922141B2 (https=)
KR (1) KR101948337B1 (https=)
CN (1) CN103298483B (https=)
AU (1) AU2011323236B2 (https=)
BR (1) BR112013011041B1 (https=)
CA (1) CA2816575C (https=)
CO (1) CO6720990A2 (https=)
DK (1) DK2635297T3 (https=)
EA (1) EA035447B1 (https=)
ES (1) ES2721478T3 (https=)
IL (1) IL226158B (https=)
MX (2) MX347503B (https=)
MY (1) MY165089A (https=)
SG (2) SG10201509149VA (https=)
WO (1) WO2012061689A2 (https=)
ZA (1) ZA201303816B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016123200A1 (en) 2015-01-30 2016-08-04 Emory University Factor viii proteins having ancestral sequences, expression vectors, and uses related thereto
KR102219859B1 (ko) 2016-06-24 2021-02-25 재단법인 목암생명과학연구소 재조합 단쇄 fviii 및 그 화학 접합물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1416348A (zh) * 2000-03-10 2003-05-07 埃默里大学 修饰的凝血因子ⅷ

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348384A (en) 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0182448A3 (en) 1984-08-24 1987-10-28 Genetics Institute, Inc. Production of factor viii and related products
ATE72838T1 (de) 1985-04-12 1992-03-15 Genetics Inst Neue prokoagulierungsproteine.
JPS6281327A (ja) 1985-10-04 1987-04-14 Green Cross Corp:The 人トロンビン製剤の加熱処理方法
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
JPS6485927A (en) 1987-09-29 1989-03-30 Green Cross Corp Hepatitis b vaccine
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
JPH0626980Y2 (ja) 1987-11-26 1994-07-20 ソニー株式会社 誤消去防止機構
WO1989009784A1 (en) 1988-04-08 1989-10-19 Commonwealth Serum Laboratories Commission Production of heat-stable factor viii concentrate
DK162233C (da) 1989-11-09 1992-03-16 Novo Nordisk As Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
IE64738B1 (en) 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
US5384132A (en) 1990-03-20 1995-01-24 Akzo N.V. Stabilized gonadotropin containing preparations
DE4111393A1 (de) 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5888974A (en) 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US6180371B1 (en) 1996-06-26 2001-01-30 Emory University Modified factor VIII
DE69329795T2 (de) 1992-10-02 2001-07-05 Genetics Institute, Inc. Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE9301581D0 (sv) 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
CA2162497A1 (en) 1993-06-10 1994-12-22 Sheila Connelly Adenoviral vectors for treatment of hemophilia
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A0 (en) 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
ZA955642B (en) 1994-07-07 1997-05-06 Ortho Pharma Corp Lyophilized imaging agent formulation
JPH0899999A (ja) 1994-09-30 1996-04-16 Chemo Sero Therapeut Res Inst α１プロテアーゼインヒビターの製造方法
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
WO1997003193A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
AU6291896A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains
PT1754718E (pt) * 1996-04-24 2011-07-13 Univ Michigan Factor viii resistente à inactivação
US7560107B2 (en) * 1996-06-26 2009-07-14 Emory University Modified factor VIII
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
WO1999029848A1 (en) 1997-12-05 1999-06-17 The Immune Response Corporation Novel vectors and genes exhibiting increased expression
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6759216B1 (en) 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
EP2921180B1 (en) 1999-02-22 2019-08-14 University of Connecticut Albumin-free factor VIII formulations
DK1194161T3 (da) 1999-07-13 2006-02-13 Biovitrum Ab Stabile faktor VIII-sammensatninger
US6333192B1 (en) 1999-08-09 2001-12-25 North Carolina State University Method of producing an undifferentiated avian cell culture using avian primordial germ cells
US6586574B1 (en) 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
US7282562B2 (en) 1999-08-31 2007-10-16 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
KR100638184B1 (ko) 2000-09-19 2006-10-26 에모리 유니버시티 변형된 인자 ⅷ
WO2003031598A2 (en) * 2001-10-05 2003-04-17 Emory University Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
AU2002364509A1 (en) 2001-11-30 2003-06-17 Emory University Factor viii c2 domain variants
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
US20050123997A1 (en) 2003-10-30 2005-06-09 Lollar John S. Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
US7939634B2 (en) 2004-01-27 2011-05-10 Compugen Ltd. Polynucleotides encoding polypeptides and methods using same
SI1750733T1 (sl) 2004-05-03 2014-03-31 Emory University POSTOPEK DAJANJA PRAĹ IÄŚJEGA fVIII BREZ DOMENE B
KR101468345B1 (ko) * 2004-11-12 2014-12-03 바이엘 헬스케어 엘엘씨 Ｆｖｉｉｉ의 부위 지향 변형
AU2007338298B2 (en) * 2006-12-22 2013-02-07 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
WO2009075772A1 (en) * 2007-12-06 2009-06-18 Wyeth Crystal structure of human factor viii and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1416348A (zh) * 2000-03-10 2003-05-07 埃默里大学 修饰的凝血因子ⅷ

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Biological activity of recombinant factor VIII variants lacking the central B-domain and the heavy-chain sequence Lys713-Arg740: discordant in vitro and in vivo activity;K Mertens et al.;《British Journal of Haematology》;19930930;134-136、140 *
Kinetics of factor VIII light-chain cleavage by thrombin and factor Xa A regulatory role of the factor VIII heavy-chain region Lys713-Arg740;Marie-Jose S. H. DONATH et al.;《Eur. J. Biochem》;19960930;365-372 *

Also Published As

Publication number Publication date
CN103298483A (zh) 2013-09-11
US20130296244A1 (en) 2013-11-07
IL226158A0 (en) 2013-06-27
BR112013011041A2 (pt) 2017-06-06
KR20140114266A (ko) 2014-09-26
EA201390654A1 (ru) 2014-01-30
EP2635297A4 (en) 2014-06-25
SG10201509149VA (en) 2015-12-30
EP2635297A2 (en) 2013-09-11
AU2011323236A1 (en) 2013-06-06
US20150353625A1 (en) 2015-12-10
JP2013545459A (ja) 2013-12-26
BR112013011041B1 (pt) 2021-05-25
EP2635297B1 (en) 2019-02-27
ZA201303816B (en) 2021-05-26
DK2635297T3 (da) 2019-05-06
MY165089A (en) 2018-02-28
CO6720990A2 (es) 2013-07-31
MX351220B (es) 2017-10-05
IL226158B (en) 2019-08-29
CA2816575C (en) 2019-06-11
ES2721478T3 (es) 2019-07-31
US10053500B2 (en) 2018-08-21
MX2013005047A (es) 2013-12-06
MX347503B (es) 2017-04-26
WO2012061689A2 (en) 2012-05-10
AU2011323236B2 (en) 2017-03-30
KR101948337B1 (ko) 2019-02-14
JP5922141B2 (ja) 2016-05-24
US9150637B2 (en) 2015-10-06
CA2816575A1 (en) 2012-05-10
SG190136A1 (en) 2013-07-31
EA035447B1 (ru) 2020-06-17
AU2011323236A8 (en) 2013-07-25
WO2012061689A3 (en) 2012-10-04

Similar Documents

Publication Publication Date Title
US5663060A (en) Hybrid human/animal factor VIII
US7928199B2 (en) Stabilized proteins with engineered disulfide bonds
JP3701028B2 (ja) 高純度フォンビルブラント因子の入手方法
ZA200206810B (en) Modified factor VIII.
CN104487452A (zh) 因子viii组合物及其制备和使用方法
JP2003174876A (ja) ブタ第ｖｉｉｉ因子ａ２ドメインをコードするｄｎａ
AU2002310438A1 (en) Stabilized proteins with engineered disulfide bonds
CN111183151B (zh) 因子viii亚种的纯化
JP2005511038A (ja) 第ｖｉｉｉ因子ｃ２ドメインのバリアント
CN103298483B (zh) 具有增加的比活性的抗血友病因子viii的新型变体
US20220259287A1 (en) Single chain factor viii molecule
EP2387582A1 (en) New process for highly selective purification of two plasma proteins: von willebrand factor (vwf) and fibronectin (fn)
HK1189486B (en) A new variant of antihemophilic factor viii having increased specific activity
HK1189486A (en) A new variant of antihemophilic factor viii having increased specific activity
Krishnan et al. Thrombin cleavage analysis of a novel antihaemophilic factor variant, factor VIII Δ II
EP3205665A1 (en) Method of separating factor viii from blood products
BR112019003302B1 (pt) Proteína de fusão fator viii de coagulação de sangue humano altamente glicosilada, molécula de dna, vetor, composição farmacêutica, e método de preparação e seu uso
HK1058946B (en) Hybrid human/porcine factor viii

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20160811

Address after: Aupu, Switzerland

Applicant after: Hundred deep limited liability company

Applicant after: Hundred deep company

Address before: Illinois State

Applicant before: Baxter International Inc.

Applicant before: Bakst Helth Co., Ltd.

GR01 Patent grant
GR01 Patent grant
CP02 Change in the address of a patent holder
CP02 Change in the address of a patent holder

Address after: Zug City

Co-patentee after: Hundred deep company

Patentee after: Hundred deep limited liability company

Address before: Aupu, Switzerland

Co-patentee before: Hundred deep company

Patentee before: Hundred deep limited liability company

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20210702

Address after: Osaka

Patentee after: TAKEDA PHARMACEUTICAL Co.,Ltd.

Address before: Zug City

Patentee before: BAXALTA GmbH

Patentee before: Baishen Co.